Genmab

	6/11 09:32 af E L	so Novo confirmed yesterday they also submitted an appliction for approval of denecimig / Mim8 to EMA in september
	6/11 07:00 af transalp	Go morgen.. :)
	6/11 01:06 af bikube	Da jeg så det, måtte jeg lige taste en gang mere på regneren - den siger 1897,4.
	5/11 23:19 af Raun	Flot dag i US - et luk lige i underkanten af 1900 under pæn omsætning
	5/11 22:20 af Pensionisten	Regnskab vel først efter markedet i DK er lukket - oplyst efter kl. 17.00 - som sædvanligt.
	5/11 17:42 af E L	seekingalpha: Genmab (GMAB) is scheduled to announce Q3 earnings results on Thursday, November 6th, before market open. The consensus EPS Estimate is $0.45 and the consensus revenue estimate is $983.65M.
	5/11 17:41 af E L	Genmab AS (GMAB, Financial) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $986.99 million, and the earnings are expected to come in at $0.46 per share. (link)
	5/11 17:41 af E L	Genmab A/S is set to announce its Q3 2025 earnings on November 6, 2025, with analysts expecting earnings of $0.47 per share and revenue of $975.4 million (link)
	5/11 16:20 af gdn55	Novo nede med ca. 3,5 Ambu 18 Zeeland 3,5 Genmab 2,5.
	5/11 16:12 af JKY_VH	Ser ud til at markedet regner med en solid opjustering. Aktien falder 2,4% pt.
	5/11 15:57 af Raun	Schyyyyy.... Opjusteringer er noget være lort for kursen
	5/11 12:59 af lahn1	Har ikke noteret mig salget fra jnj og de øvrige partnere helt næøjagtigt, men vi ligger vel til en opjustering
	5/11 08:55 af E L	TEPEZZA ® (teprotumumab-trbw) sales increased 15% year-over-year to $560 million in the third quarter, driven by higher inventory levels and higher net selling price (link)
	4/11 17:31 af Helge Larsen/PI-redaktør	Knock-Your-Socks-Off-News – November 2025 (link)
	4/11 16:58 af E L	Pfizer Q3 2025 Tivdak $37mn , YTD $115mn . Now i don't know if this is the full number, as somewhere this year Genmab would assume more responsibilities for Tivdak / leading commercialization in Europe , so not sure who books what at the moment...
	4/11 12:09 af lahn1	Det koster blod, sved og tåre at være investeret i biotech. Jeg har sprugt meget i flere år :-) Skriv en liste på alle de forkortelser og akronymer du har mødt, så er jeg sikker på de profesionelle her på PI er villige til at forklare. Det er min erfaring.
	4/11 12:09 af SEACOP	Jeg nyder det høje niveau i dette forum, hvor jeg lærer meget. Det, som jeg ikke forstår, springer jeg nemt over. For mig findes kun dette sted, hvis jeg vil have god indsigt. Fortsæt venligst. Tak.
	4/11 10:45 af Bella1	Tak, npo
	4/11 10:06 af npo	My two cents : Whereas writer – and I trust other investors - appreciate in-put with a technical background from professionals in this forum. Regrettably, however, due to use of acronyms and abbreviations in-put often becomes so technical it often comes across gobbledygook – incomprehensible to ordinary mortals (investors). Use of “simpler” terms and less acronyms etc. could enable/attract more investors to read and follow progress and in the process be attracted to support Genmab.
	4/11 09:20 af lahn1	Er det bare mig eller bliver real world data på Epco og Glofi udlagt negativt. Man kan jo ikke sammenligne trials hvor pts skal være CD20 +ve med real world data i 3L hvor 80% af pts har tabt CD20 expression. Nogen som har et bud på om dette vil ændre peak sales på Epco ? Søg på Epcoritamab på X og jeg syntes budskabet er epco/Glofi præsterer dårligere i real life end i trials.
	3/11 18:01 af E L	the FDA reversed its previous position on a sBLA for UniQure and the stock drops 56%. not sure if that is what drives biotech sentiment this US morning but not a good bio-start for november...
	3/11 17:42 af E L	;-)
	3/11 17:41 af Plimsoller	Thank you :-)
	3/11 17:41 af Plimsoller	More wants more ;-)

	3/11 16:57 af E L	i think the FL abstracts are important, in combination with the potential FDA approval late this month
	3/11 16:56 af E L	was this still not enough Plimsoller??? :-) there is always a chance, but only very few LBA's , i think last year only 6 or so
	3/11 16:43 af Solsen	7 orale præsentationer er flot. Biontech afholder en R&D update den 11. november, som kan være interessant som Genmab investor.
	3/11 16:38 af Plimsoller	That's a long list E L :-) Any chance of a late breaking abstract?
	3/11 16:09 af E L	Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting (link)
	3/11 16:05 af E L	ASH 2025 . enjoy. (link)
	3/11 15:15 af E L	GEN1059 and GEN1042 still in the Biontech pipeline at Q3 25...
	3/11 12:09 af Plimsoller	Vi må ikke håbe at det er 2200 svenske kroner ;-)
	3/11 10:36 af ProInvestorNEWS	Genmab får hævet kursmålet til 2200 kr. hos svensk storbank (link)
	3/11 10:15 af Peter Panik	ja til 2200
	3/11 10:15 af Peter Panik	Handelsbanken hæver kursmål fra 2000 til 2000
	1/11 10:41 af E L	Merus SCHEDULE 14A NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF MERUS N.V. TO BE HELD (link)
	1/11 10:26 af transalp	Go weekend.. :)
	31/10 17:20 af E L	Genmab and cancer drugmaker Merus have filed paperwork with the US antitrust authorities for their $8 billion deal and the waiting period under the Hart-Scott-Rodino Act is set to expire on Nov. 12
	31/10 14:52 af E L	Roche YTD Lunsumio 77 + Columvi 202 = 279CHF ~= USD 347, so it is very close to Epkinly (AbbVie only reports it's share, so it will be a bit less than 2 x 190)
	31/10 14:51 af E L	Epkinly Q3 2025 AbbVie 21 + 48 = 69, YTD 190 ( (link) ) (versus Q2 2025 AbbVie 22 + 48 = 70)
	31/10 10:27 af bibob	God formiddag :-)
	31/10 10:18 af E L	lahn referred to this the other day- The month ahead: November’s upcoming events - Epkinly expansion? (link)
	31/10 09:54 af JKY_VH	Afskedssalut fra Novod "Investment case We believe the Genmab stock is undervalued, both on a DCF valuation and based on high single-digit to low double-digit P/E multiples in 2026E-27E. We see upside to our peak sales estimates for Epkinly and Rina-S, and think that Genmab is very well funded with more than USD 3bn in cash."
	31/10 09:44 af JKY_VH	Flash "Nordea höjer riktkursen för Genmab till 2 021 danska kronor (2 000), upprepar köp"
	31/10 09:41 af E L	Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy (link)
	31/10 07:54 af LP90	Godmorgen :-)
	31/10 07:45 af Helge Larsen/PI-redaktør	Godmorgen :-)
	30/10 19:07 af lahn1	Og lige i tide til at blive en late breaking abstract på ASH
	30/10 18:59 af lahn1	Gad vide hvad taget event var i det studie. var den 70% og en HR 0.60. så kunne mOS være 26-34 mdr. :o
	30/10 17:51 af Raun	Det må vel også betyde at jo længere tid der går - jo bedre?